The PSIL ETF is an actively managed exchange-traded fund that selectively invests in life sciences companies involved in psychedelic-based pharmaceuticals and mental health treatment. The portfolio is built mainly around companies with clear revenue or asset exposure to related businesses.

It suits investors who can accept large swings tied to drug development progress and policy changes, and who are looking at the long-term growth potential of the mental health treatment theme.

It is an ETF with an active management approach, run by AdvisorShares.

The PSIL ETF mainly targets publicly listed life sciences companies with clear related revenue or asset exposure. It reviews stocks listed in the US and abroad, and where direct ownership is difficult it may use derivative contracts, so investors should also watch its cash weighting and changes in composition.

• Concentrated in the psychedelic pharmaceutical theme
• Actively managed with company selection

Assets under management (AUM) stand at $43.6M, and the total expense ratio is 1.00% per year.

Given the nature of a thematic active product, the manager's judgments on holdings' clinical progress, financial condition, and policy environment can affect both performance and volatility. Because public holdings data is limited under this drafting standard, individual stocks are not cited.

The performance of the PSIL ETF can react sensitively to clinical results, approval procedures, funding conditions, and shifts in market expectations for mental health treatment. The higher the weighting of early-stage companies, the more likely it is that individual research results and regulatory news will cause large short-term swings.

Fund flows can depend on risk appetite for the theme and on sentiment toward the biotech sector. If interest rates and capital market conditions change, the funding environment for companies that have yet to generate stable cash flow can change as well, so it is necessary to check holdings weights and management updates regularly.

Thematic concentration and active stock selection are points of differentiation, but regulatory and clinical uncertainty and industry concentration can deepen losses.

In the automated comparison table, the DRAM ETF is a thematic product focused on memory-related companies, the SECT ETF uses a sector rotation approach, the AVRE ETF offers real estate exposure, the VOLT ETF covers the electrification theme, and the CANC ETF covers oncology. None of these directly substitutes for the psychedelic pharmaceutical theme, so when comparing them with the PSIL ETF, investors should also look at differences in fees, management style, and industry exposure. Comparable listed fund information is limited.

When reviewing the PSIL ETF, do not look only at the long-term appeal of the theme itself. Also check the holdings' clinical progress, regulatory conditions, funding environment, and portfolio concentration. As a thematic active product, it is important to make a habit of checking changes in official management materials.

The business environment of the psychedelic-related pharmaceutical industry can change quickly depending on legislation, approvals, and social acceptance. Because the PSIL ETF can be concentrated in specific industries and companies, both positive research news and negative clinical results can have a large impact on the fund's value.

The PSIL ETF is an active product for investors who want access to psychedelic-based pharmaceuticals and the mental health treatment theme. However, rather than judging it on the theme's growth potential alone, it is advisable to review it after weighing regulatory and clinical risk, industry concentration, and the financial condition of individual companies, in line with your own risk tolerance.